


AMENDMENTS TO THE CLAIMS

1.-48. (Cancelled)

49. (Currently amended) A compound of general formula I



wherein

R_1 is ~~halogen, hydroxy, mercapto, trifluoromethyl, amino, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-6} alkylamino, C_{1-4} alkoxycarbonyl, cyano, $CONH_2$ or nitromethyl;~~

R_2 is ~~halogen, hydroxy, mercapto, trifluoromethyl, amino, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-6} alkylamino, C_{1-4} alkoxycarbonyl, cyano, $CONH_2$, phenyl or nitrochloro;~~

R_3 represents fluoro;

R_4 is fluoro;

wherein R_3 is in the meta position with respect to R_4 and para with respect to $-NH-$;

R_a , R_b and R_c are the same or different, each representing hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-8} carbocyclyl, C_{1-12} heterocyclyl or aryl, each of C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-8} carbocyclyl, C_{1-12} heterocyclyl or aryl being optionally substituted by one or more, same or different substituents represented by R_7 ;

R₇ is halogen, hydroxy, mercapto, trifluoromethyl, amino, C₁₋₄alkyl, C₁₋₆hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkylthio, C₁₋₆alkylamino, C₁₋₄alkoxycarbonyl, C₁₋₉trialkylammonium in association with an anion, cyano, azido, nitro, -S(O)₂NH₂, -S(O)₂NR_aR_b, -S(O)₂R, -COOH, -CONH₂, -NR_aC(O)R', -CONHR' or -CONRR', wherein R and R' are same or different, each representing hydrogen or C₁₋₃alkyl;

one of R₅ and R₆ is -COOH, -C(O)NHOH, -C(O)NHNH₂, Y₂R₉, Y₂R₉Y₃R₁₀, C₁₋₆alkyl-Y₂R₉, C₁₋₆alkyl-Y₂R₉Y₃R₁₀, C₂₋₆alkenyl-Y₂R₉, C₂₋₆alkenyl-Y₂R₉Y₃R₁₀, Y₂R₉-C₁₋₆alkyl-Y₃R₁₀, Y₂R₉-C₂₋₆alkenyl-Y₃R₁₀, C₃₋₁₂carbocyclyl-Y₂R₉, C₃₋₁₂carbocyclyl-Y₂R₉Y₃R₁₀, C₁₋₁₂heterocyclyl-Y₂R₉, C₁₋₁₂heterocyclyl-Y₂R₉Y₃R₁₀, C₃₋₁₂carbocyclyl-C₁₋₆alkyl-Y₂R₉, C₃₋₁₂carbocyclyl-C₁₋₆alkyl-Y₂R₉Y₃R₁₀, C₁₋₁₂heterocyclyl-C₁₋₆alkyl-Y₂R₉, C₁₋₁₂heterocyclyl-C₁₋₆alkyl-Y₂R₉Y₃R₁₀, C₃₋₁₂carbocyclyl-C₁₋₆alkyl-Y₃R₁₀, C₁₋₁₂heterocyclyl-C₁₋₆alkyl-Y₃R₁₀, C₁₋₁₂heterocyclyl-C₁₋₁₀alkyl, C₃₋₁₂carbocyclyl-C₁₋₁₀alkyl, C₁₋₁₀alkyl-C₁₋₁₂heterocyclyl, C₁₋₁₀alkyl-C₃₋₁₂carbocyclyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂carbocyclyl or C₁₋₁₂heterocyclyl, each of which being optionally substituted by one or more, same or different substituents represented by R₇, and the other is hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkylthio, C₁₋₆alkylamino, C₁₋₄alkoxycarbonyl, cyano, -CONH₂ or nitro,

with the proviso that when R₅ or R₆ is phenyl, C₁₋₅alkyl or C₂₋₃alkenyl, said R₅ or R₆ is substituted by one or more, same or different substituents represented by R₇ (except three fluorine when R₅ or R₆ is methyl),

Y₂ is -O-, -S-, -S(O)-, -S(O)₂-, -NR_a-, -NR_aC(O)NR_b-, -NR_aC(O)-, -C(O)NR_a-, -C(O)NR_aO-, -C(O)-, -NR_aC(O)O-, -NR_aS(O)₂-, -OC(O)-, -C(O)O-, -C(O)NR_aNR_bC(S)NR_c-, -C(O)NR_aNR_b-, or -S(O)₂NR_a-;

R₉ is C₁₋₁₀alkyl-C₁₋₁₂heterocyclyl, C₁₋₁₀alkyl-C₃₋₁₂carbocyclyl, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₂carbocyclyl, C₁₋₁₂heterocyclyl, C₃₋₁₂carbocyclyl-C₁₋₁₀alkyl, or C₁₋₁₂heterocyclyl-C₁₋

$_{10}$ alkyl, C_{3-6} carbocyclyl- C_{1-6} alkenyl, C_{3-6} carbocyclyl- C_{2-6} alkynyl, each being optionally substituted by one or more, same or different substituents represented by R_7 ,

with the proviso that when Y_2 is $-O-$, $-NR_a-$, $-S-$ or $-C(O)O-$, and R_9 is C_{1-6} alkyl, said C_{1-6} alkyl is substituted by one or more, same or different substituents represented by R_7 ;

Y_3 is $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-NR_a-$, $-NR_aC(O)NR_b-$, $-NR_aC(O)-$, $-C(O)NR_a-$, $-C(O)NR_aO-$, $-C(O)-$, $-NR_aC(O)O-$, $-NR_aS(O)_2-$, $-OC(O)-$ or $-C(O)O-$;

R_{10} is C_{1-10} alkyl- C_{1-12} heterocyclyl, C_{1-10} alkyl- C_{3-12} carbocyclyl, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-12} carbocyclyl or C_{1-12} heterocyclyl, each being optionally substituted by one or more, same or different substituents represented by R_7 ;

or, when one of R_5 or R_6 is the group $-C(O)NR_aR_9$, R_a and R_9 together with the nitrogen atom to which they are attached form a C_{1-12} heterocyclic ring optionally comprising one or more additional heteroatoms selected from the group consisting of O, S and N, optionally substituted with one or more substituents represented by R_7 ;

or a pharmaceutically acceptable salt, solvate, or ester thereof.

50—62. (Cancelled).

63. (Previously presented) A compound according to claim 49, wherein R_7 is halogen, hydroxy, amino, $-S(O)_2CH_3$, trifluoromethyl, cyano, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkyl, C_{1-4} alkylthio, C_{1-4} alkylamino, C_{1-4} alkoxycarbonyl, $-COOH$, $-CONH_2$, $-S(O)_2NH_2$, azido, $-CONHR'$ or $-CONRR'$, wherein R and R' are as indicated in claim 49.

64. (Previously presented) A compound according to claim 49, wherein R_7 is methyl, ethyl, methoxy, ethoxy, hydroxy, methoxycarbonyl, ethoxycarbonyl, dimethylamino, ethylamino, amino, $-\text{COOH}$, fluoro, chloro, bromo, $-\text{CONH}_2$, $-\text{S}(\text{O})_2\text{NH}_2$, azido, methylthio, $-\text{S}(\text{O})_2\text{CH}_3$, trifluoromethyl, cyano or hydroxymethyl.

65. (Previously Presented) A compound according to claim 49, wherein one of R_5 and R_6 is Y_2R_9 , $\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9$, $\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{C}_{2-4}\text{alkenyl}-\text{Y}_2\text{R}_9$, $\text{C}_{2-4}\text{alkenyl}-\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{Y}_2\text{R}_9-\text{C}_{1-4}\text{alkyl}-\text{Y}_3\text{R}_{10}$, $\text{Y}_2\text{R}_9-\text{C}_{2-4}\text{alkenyl}-\text{Y}_3\text{R}_{10}$, $\text{C}_{1-6}\text{heterocyclyl}-\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9$, $\text{C}_{1-4}\text{alkyl}-\text{C}_{1-6}\text{heterocyclyl}$, $\text{C}_{1-4}\text{alkyl}-\text{C}_{3-6}\text{carbocyclyl}$, $\text{C}_{3-6}\text{carbocyclyl}-\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}$ substituted by R_7 , $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{3-6}\text{carbocyclyl}$, $\text{C}_{1-6}\text{heterocyclyl}$, $-\text{COOH}$, $-\text{C}(\text{O})\text{NHOH}$, or $\text{C}(\text{O})\text{NHNH}_2$, and the other is hydrogen, halogen, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-4}\text{alkoxy}$; wherein R_9 is $\text{C}_{1-4}\text{alkyl}-\text{C}_{1-6}\text{heterocyclyl}$, $\text{C}_{1-4}\text{alkyl}-\text{C}_{3-6}\text{carbocyclyl}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{3-10}\text{carbocyclyl}$, $\text{C}_{1-6}\text{heterocyclyl}$, $\text{C}_{3-6}\text{carbocyclyl}-\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{heterocyclyl}-\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{carbocyclyl}-\text{C}_{2-4}\text{alkenyl}$ or $\text{C}_{3-6}\text{carbocyclyl}-\text{C}_{2-4}\text{alkynyl}$; and wherein R_{10} is $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{3-6}\text{carbocyclyl}$ or $\text{C}_{1-6}\text{heterocyclyl}$.

66. (Previously Presented) A compound according to claim 49, wherein R_5 is Y_2R_9 , $\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9$, $\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{C}_{2-4}\text{alkenyl}-\text{Y}_2\text{R}_9$, $\text{C}_{2-4}\text{alkenyl}-\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, $\text{Y}_2\text{R}_9-\text{C}_{1-4}\text{alkyl}-\text{Y}_3\text{R}_{10}$, $\text{Y}_2\text{R}_9-\text{C}_{2-4}\text{alkenyl}-\text{Y}_3\text{R}_{10}$, $\text{C}_{1-6}\text{heterocyclyl}-\text{C}_{1-4}\text{alkyl}-\text{Y}_2\text{R}_9$, $\text{C}_{1-4}\text{alkyl}-\text{C}_{1-6}\text{heterocyclyl}$, $\text{C}_{1-4}\text{alkyl}-\text{C}_{3-6}\text{carbocyclyl}$, $\text{C}_{3-6}\text{carbocyclyl}-\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}$ substituted by R_7 , $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{3-6}\text{carbocyclyl}$, $\text{C}_{1-6}\text{heterocyclyl}$, $-\text{COOH}$, $-\text{C}(\text{O})\text{NHOH}$, or $\text{C}(\text{O})\text{NHNH}_2$, and R_6 is hydrogen, halogen, $\text{C}_{1-4}\text{alkyl}$ or $\text{C}_{1-4}\text{alkoxy}$; wherein R_9 is $\text{C}_{1-4}\text{heterocyclyl}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-3}\text{alkyl}-\text{C}_{1-5}\text{heterocyclyl}$, $\text{C}_{6-10}\text{carbocyclyl}$, $\text{C}_{1-3}\text{alkyl}-\text{C}_6\text{carbocyclyl}$, $\text{C}_3\text{alkenyl}$, $\text{C}_6\text{carbocyclyl}-\text{C}_1\text{alkyl}$, $\text{C}_6\text{carbocyclyl}-\text{C}_3\text{alkenyl}$ or $\text{C}_6\text{carbocyclyl}-\text{C}_2\text{alkynyl}$; and wherein R_{10} is methyl, ethyl, methacryl, tert-butyl, tetrahydropyranyl or ethenyl.

67. (Previously presented) A compound according to claim 49, wherein one of R_5 and R_6 is Y_2R_9 , $\text{Y}_2\text{R}_9\text{Y}_3\text{R}_{10}$, phenyl, methylphenyl, methyl, propenyl, methyl- Y_2R_9 , tetrazole, ethynyl, triazole, thiadiazole, dihydrooxazole, $-\text{COOH}$, $-\text{C}(\text{O})\text{NHOH}$, or $\text{C}(\text{O})\text{NHNH}_2$, and the other is

hydrogen, fluoro, chloro, methyl or methoxy; wherein R₉ is morpholinyl, propylmorpholinyl, piperazinyl, methyl, ethyl, n-propyl, n-butyl, *tert*-butyl, isobutyl, hexyl, isopropyl, dimethylpropyl, methyltetrahydrofuranyl, methylpyridinyl, ethylpiperazinyl, cyclohexyl, propyloxopyrrolidinyl, benzyl, methylcyclohexyl, propylphenyl, ~~ethylphenyl~~, ethylmorpholinyl, allyl, ethylfuranyl, phenyl, methyldioxoimidazolidinyl, dioxohexahydropyrimidinyl, thiazolyl, methylphenyl, ethylphenyl, methyldioxolanyl, methylthiazolyl, propenylphenyl, methylfuranyl, thiophenyl, tetrahydropyranyl or ethynylphenyl; and wherein R₁₀ is methyl, ethyl, methacryl, *tert*-butyl, tetrahydropyranyl or ethenyl.

68. (Previously Presented) A compound according to claim 49, wherein R₆ is hydrogen.

69. (Previously Presented) A compound according to claim 49, wherein R₅ is hydrogen.

70. (Previously Presented) A compound according to claim 49, wherein Y₂ is -O-, -NR_a-, -NR_aC(O)NR_b-, -NR_aC(O)-, -C(O)NR_a-, -C(O)NR_aO-, -C(O)-, -NR_aC(O)O-, -NR_aS(O)₂-, -C(O)NR_aNR_b- or -S(O)₂NR_a-.

71. (Previously Presented) A compound according to claim 49, wherein Y₃ is -O-, -NR_aC(O)-, -C(O)NR_a-, -C(O)-, -C(O)O- or -NR_aC(O)O-.

72.—76. (Cancelled)

77. (Previously Presented) A compound according to claim 49, wherein said heterocycle or heterocyclyl contains one or two oxygen atoms or one sulphur atom, and/or up to two nitrogen atoms, or three or four nitrogen atoms, wherein optionally one or two CH₂ ring fragments is/are replaced by one or two -C(O)- fragments respectively.

78. (Previously Presented) A compound according to claim 49, wherein R_a, R_b, or R_c independently represent hydrogen, methyl, ethyl, 2-hydroxyethyl or 2-methoxyethyl.

79. (Cancelled).

80. (Currently amended) A compound according to claim 49 selected from the group consisting of

3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-*N*-(2-hydroxyethyl)-4-methylbenzamide
(Compound 115),

~~3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methoxy-benzamide
(compound 140),~~

~~3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,2-difluoro-ethyl)-4-methoxy-
benzamide (compound 141),~~

~~3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-fluoro-ethyl)-4-methoxy-benzamide
(compound 142),~~

~~3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methoxy-
benzamide (compound 143),~~

~~*N*-Carbamoylmethyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzamide
(compound 144),~~

N-Carbamoylmethyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide
(Compound 145),

N-Benzyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound
146),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-fluoro-ethyl)-4-methyl-benzamide
(compound 147),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2,2,2-trifluoro-ethyl)-
benzamide (compound 148),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-ethyl-4-methyl-benzamide (compound
149),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexylmethyl-4-methyl-benzamide
(compound 150),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-propyl)-4-methyl-benzamide (compound 151),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methyl-benzamide (compound 152),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(1-hydroxymethyl-propyl)-4-methyl-benzamide (compound 153),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2,2,3,3,3-pentafluoro-propyl)-benzamide (compound 154),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-hydroxy-propyl)-4-methyl-benzamide (compound 155),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-1,1-dimethyl-ethyl)-4-methyl-benzamide (compound 156),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-1-hydroxymethyl-1-methyl-ethyl)-4-methyl-benzamide (compound 157),
{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetic acid ethyl ester (compound 158),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(4-hydroxy-butyl)-4-methyl-benzamide (compound 159),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-hydroxy-1,1-dimethyl-butyl)-4-methyl-benzamide (compound 160),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(3-phenyl-propyl)-benzamide (compound 161),
(*R*)-3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(1-hydroxymethyl-3-methyl-butyl)-4-methyl-benzamide (compound 162),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-isopropyl-4-methyl-benzamide (compound 164),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexyl-4-methyl-benzamide (compound 165),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,2-difluoro-ethyl)-4-methyl-benzamide (compound 166),

5-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-4-oxo-pentanoic acid methyl ester (compound 167),

N-[(2-Carbamoyl-ethylcarbamoyl)-methyl]-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 168),

(2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-acetylamino)-acetic acid ethyl ester (compound 169),

N-Allyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 170),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-sulfamoyl-ethyl)-benzamide (compound 171),

N-(2-Acetylamino-ethyl)-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 172),

~~4-Chloro-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-benzamide (compound 204),~~

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methoxy-propionamide (compound 241),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-propionamide (compound 242),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-(2-methoxy-ethoxy)-acetamide (compound 243),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-morpholin-4-yl-propionamide (compound 244),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-hydroxy-propionamide (compound 245),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-furan-2-yl-propionamide (compound 246),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-hydroxy-benzamide (compound 247),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-2-(2,5-dioxo-imidazolidin-4-yl)-acetamide (compound 248),

2,6-Dioxo-hexahydro-pyrimidine-4-carboxylic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-amide (compound 249),

Acrylic acid 2-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenylcarbamoyl}-ethyl ester (compound 250),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methylsulfanyl-propionamide (compound 251),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-methanesulfonyl-propionamide (compound 252),

Ethanesulfonic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-amide (compound 253),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-4-methoxy-benzenesulfonamide (compound 254),

N-(5-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenylsulfamoyl}-4-methyl-thiazol-2-yl)-acetamide (compound 255),

5-Acetyl-2-chloro-*N*-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-benzenesulfonamide (compound 256),

Naphthalene-2-sulfonic acid {3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-amide (compound 257),

N-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-*C*-phenyl-methanesulfonamide (compound 258),

2-Methyl-acrylic acid 2-(3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-ethyl ester (compound 259),

1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(2-hydroxy-ethyl)-urea (compound 260),

(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-acetic acid ethyl ester (compound 261),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-methoxy-phenyl)-urea (compound 262),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-trifluoromethyl-phenyl)-urea (compound 263),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-propyl-urea (compound 264),
3-(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-propionic acid ethyl ester (compound 265),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-cyclohexyl-urea (compound 266),
1-Allyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 267),
1-Benzyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 268),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-ethyl-urea (compound 269),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-phenyl-urea (compound 270),
1-Butyl-3-{3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-urea (compound 271),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-phenethyl-urea (compound 272),
2-(3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-ureido)-benzoic acid methyl ester (compound 273),
1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(3-cyano-phenyl)-urea (compound 274),

1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-isopropyl-urea (compound 275),

1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-(4-methoxy-phenyl)-urea (compound 276),

{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid benzyl ester (compound 277),

{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid allyl ester (compound 278),

{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-carbamic acid ethyl ester (compound 279),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-butylamino)-2-methyl-phenyl]-methanone (compound 281),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3'-hydroxymethyl-4-methyl-biphenyl-3-yl)-methanone (compound 282),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3'-hydroxy-4-methyl-biphenyl-3-yl)-methanone (compound 283),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(4'-methoxy-4-methyl-biphenyl-3-yl)-methanone (compound 284),

N-{3'-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4'-methyl-biphenyl-3-yl}-acetamide (compound 285),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(4-methyl-3'-trifluoromethoxy-biphenyl-3-yl)-methanone (compound 286),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3',4',5'-trifluoro-4-methyl-biphenyl-3-yl)-methanone (compound 288),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(3',4'-dimethoxy-4-methyl-biphenyl-3-yl)-methanone (289),

3'-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4'-methyl-biphenyl-3-carbonitrile (compound 290),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-4-methyl-benzenesulfonamide (compound 291),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-morpholin-4-yl-ethyl)-benzenesulfonamide (compound 292),
N-Allyl-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzenesulfonamide (compound 293),
N-(2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzenesulfonylamino}-ethyl)-acetamide (compound 294),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-propyl-benzenesulfonamide (compound 295),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2,3-dihydroxy-propyl)-4-methyl-benzenesulfonamide (compound 296),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-methoxy-ethyl)-4-methyl-benzenesulfonamide (compound 297),
~~[4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(4-methoxy-benzoyloxy)-2-methyl-phenyl]-methanone (Compound 306),~~
~~[4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(3-hydroxy-propoxy)-2-methyl-phenyl]-methanone (Compound 307),~~
~~[2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 308),~~
~~[4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[2-methyl-5-(2-morpholin-4-yl-ethoxy)-phenyl]-methanone (compound 309),~~
~~[2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[2-methyl-5-(2-morpholin-4-yl-ethoxy)-phenyl]-methanone (compound 310),~~
~~[4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-methyl-phenyl]-methanone (compound 311),~~
~~[4-(2,4-Difluoro-phenylamino)-2-nitro-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 312),~~

~~[2-Amino-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-methyl-phenyl]-methanone (compound 313),~~
~~[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[2-fluoro-5-(3-hydroxy-propoxy)-phenyl]-methanone (compound 314),~~
~~[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-2-fluoro-phenyl]-methanone (compound 315),~~
~~[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(2,3-dihydroxy-propoxy)-2-fluoro-phenyl]-methanone (Compound 316),~~
[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-hydroxymethyl-2-methyl-phenyl)-methanone (compound 331),
[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-chloromethyl-2-methyl-phenyl)-methanone (compound 332),
(5-Azidomethyl-2-methyl-phenyl)-[2-chloro-4-(2,4-difluoro-phenylamino)-phenyl]-methanone (compound 333),
(5-Aminomethyl-2-methyl-phenyl)-[2-chloro-4-(2,4-difluoro-phenylamino)-phenyl]-methanone (compound 334),
~~[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-hydroxymethyl-2-methoxy-phenyl)-methanone (compound 335),~~
~~Acetic acid 3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzyl ester (compound 336),~~
~~*N-tert*-Butoxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzamide (compound 337),~~
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-methoxy-4-methyl-benzamide (compound 338),
N-Butoxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 339),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-cyclohexylmethoxy-4-methyl-benzamide (compound 340),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-(2-methyl-thiazol-4-ylmethoxy)-benzamide (compound 341),
N-benzyloxy-3-[2-chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzamide (compound 342),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(4-methoxy-benzyloxy)-4-methyl-benzamide (compound 343),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoic acid *N,N'*-dimethyl-hydrazide (compound 344),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-*N*-morpholin-4-yl-benzamide (compound 345),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-hydroxy-4-methyl-benzamide (compound 346),
4-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(2-hydroxy-ethyl)-3-methyl-benzamide (compound 347),
[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(3-hydroxy-propenyl)-2-methyl-phenyl]-methanone (compound 348),
4-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-3-carboxylic acid methyl ester (compound 349),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-furan-2-ylmethyl-4-methyl-benzamide (compound 350),
3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-(3-methoxy-phenyl)-4-methyl-benzamide (compound 351),
2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-benzoic acid methyl ester (compound 352),
3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-2-carboxylic acid methyl ester (compound 353),
4-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-3-carboxylic acid (compound 354),

2-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-benzoic acid (compound 355),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-*N*-[2-(2-hydroxy-ethylcarbamoyl)-phenyl]-4-methyl-benzamide (compound 356),

3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoylamino}-thiophene-2-carboxylic acid (2-hydroxy-ethyl)-amide (compound 357),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-(5-ethynyl-2-methyl-phenyl)-methanone (compound 362),

3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoic acid hydrazide (compound 364),

1-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-benzoyl}-4-ethyl-3-thio semicarbazide (compound 365),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(5-ethylamino-[1,3,4]thiadiazol-2-yl)-2-methyl-phenyl]-methanone (compound 366),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[2-methyl-5-(1H-tetrazol-5-yl)-phenyl]-methanone (compound 367),

3-{3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methyl-phenyl}-3-oxo-propionic acid ethyl ester (compound 368),

[2-Chloro-4-(2,4-difluoro-phenylamino)-phenyl]-[5-(4,5-dihydro-oxazol-2-yl)-2-methyl-phenyl]-methanone (compound 369),

3-[2-Chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoic acid (Compound 424),

2-Methylacrylic acid 2-{3-[2-chloro-4-(2,4-difluorophenylamino)benzoyl]-4-methylbenzoylamino}ethyl ester (Compound 425),

~~3-[2-Chloro-4-(2,4-difluoro-phenylamino)-benzoyl]-4-methoxy-benzoic acid (compound 437).~~


81. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 49 or a pharmaceutically acceptable salt or ester thereof together with a pharmaceutically acceptable vehicle or excipient.

82. (Cancelled)

83. (Withdrawn) A method of preventing, treating or ameliorating inflammatory diseases or conditions, or ophthalmic diseases or conditions, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 49, wherein the inflammatory or ophthalmic disease or condition is selected from the group consisting of asthma, allergy, arthritis, rheumatoid arthritis, spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease, Crohn's disease, neurological inflammations, inflammatory eye diseases, proliferative and inflammatory skin disorders, psoriasis, atopic dermatitis, acne, uveitis, sepsis, septic shock or acne, and osteoporosis.


84.-87. (Cancelled)

88. (Withdrawn) A method for producing a compound of general structure I,



wherein R₁, R₂, R₃, R₄, R₅, and R₆ are defined as in claim 49, comprising the steps of


a) transforming a compound general structure VI,




wherein Hal is a halogen, and R_1 , R_5 and R_6 are defined as in claim 49, each of which are independently protected or unprotected, into an organometallic intermediate;

b) transmetalating said organometallic intermediate to an organozinc intermediate;

c) coupling said organozinc intermediate with an acid halide of general structure V,




wherein R_2 is defined as in claim 49, protected or unprotected, in the presence of a catalyst to give a compound of general structure IV,



wherein R_1 , R_2 , R_5 , and R_6 are defined as above, each of which are independently protected or unprotected;

d) optionally transforming, protecting or deprotecting one or more substituents or functional groups of R_1 , R_2 , R_5 , and R_6 of the compound of general structure IV to give another compound of general structure IV;


e) reducing the compound of general structure IV from step c) or d) to an amine of general structure III,



wherein R_1 , R_2 , R_5 , and R_6 are defined as above, each of which are independently protected or unprotected;

f) optionally transforming, protecting or deprotecting one or more substituents or functional groups of R_1 , R_2 , R_5 , and R_6 of the compound of general structure III to give another compound of general structure III;


g) coupling of the amine of general structure III from step e) or f) with a compound of general structure II,



wherein L is triflate or halogen, R_3 and R_4 are defined in claim 49, each of which are independently protected or unprotected, to give a compound of general structure I, wherein R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are defined as above, each of which are independently protected or unprotected;


h) optionally transforming, protecting or deprotecting one or more substituents or functional groups of R_1 , R_2 , R_3 , R_4 , R_5 , or R_6 of the compound of general structure I from step g) to give a another compound of general structure I.

89. (Withdrawn) A method for producing a compound of general structure I,



wherein R₁, R₂, R₃, R₄, R₅, and R₆ are defined as in claim 49, comprising the steps of


a) transforming a compound general structure VIIa,




wherein Hal is halogen, W is halogen or triflate, and R₂ is as defined in claim 49, protected or unprotected, into an organometallic intermediate;

b) transmetalating said organometallic intermediate to an organozinc intermediate;

c) coupling said organozinc intermediate with an acid halide of general structure VIII,




wherein R₁, R₅, and R₆ are as defined in claim 49, each of which are independently protected or unprotected, in the presence of a catalyst to give a compound of general structure IIIa,



wherein W, R₁, R₂, R₅, and R₆ are defined as above, each of which are independently protected or unprotected;

d) optionally transforming, protecting or deprotecting one or more substituents or functional groups of W, R₁, R₂, R₅, and R₆ of the compound of general structure IIIa to give another compound of general structure IIIa;

e) coupling of the compound of general structure IIIa from step c) or d) with an amine of general structure IIa,



wherein R₃ and R₄ are defined as in claim 49, each of which are independently protected or unprotected, to give a compound of general structure I,

wherein R₁, R₂, R₃, R₄, R₅, and R₆ are defined as above, each of which are independently protected or unprotected;

f) optionally transforming, protecting or deprotecting one or more substituents or functional groups of R₁, R₂, R₃, R₄, R₅, or R₆ of the compound of general structure I from step e) to give another compound of general structure I.

90. (Cancelled)

91. (Previously Presented) A composition according to claim 81 further comprising another active component selected from the group consisting of glucocorticoids, vitamin D analogues, anti-histamines, platelet activating factor (PAF) antagonists, anticholinergic agents, methyl xanthines, β -adrenergic agents, COX-2 inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicilamine, serum cholesterol reducing agents, retinoids, zinc salts and salicylazosulfapyridin.

92. (Withdrawn) A method of preventing, treating or ameliorating acute macular degeneration or age-related macular degeneration, the method comprising administering to a patient in need thereof an effective amount of a compound according to claim 49.